News for Healthier Living

Real-World Study Provides New Insights into Safety of New Alzheimer's Drug

Researchers at Duke Health studied more than 230 patients treated with lecanemab, a new FDA-approved therapy (known as an anti-amyloid therapy) designed to remove a protein linked to Alzheimer's disease from the brain. They found the therapy's real-world safety, treatment persistence, and effects on disease progession aligned with results from clinical trials - including the most closely watched side effect, which involves brain swelling or bleeding, commonly referred to as Amyloid Related Imaging Abnormalities (ARIA).

August 7, 2026


August 12 2026

August 11 2026

August 10 2026

August 7 2026

August 6 2026

August 5 2026

August 4 2026

August 3 2026

August 1 2026

July 31 2026

July 30 2026